Table 1. Growth inhibition with microtubule disrupting agents.
Human cells were plated in 96-well plates, allowed to attach for 24 h and treated for 72 h with DMSO or a range of concentrations of test agents. Cell number was determined spectrophotometrically at 570 nm minus absorbance at 690 nm after exposure to 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) or by measuring fluorescence (excitation = 560, emission = 590) in live cells using the Cell Titer Blue Assay (Promega, Madison, WI).
| Cell Line | Description | IC50 (nM) ± SEMa | ||
|---|---|---|---|---|
| Disorazole C1 | Vincristine | Vinblastine | ||
| A549 | Lung carcinoma | 2.21 ± 0.23 | 21.62 ± 2.68 | 1.52 ± 0.09 |
| PC-3 | Prostate adenocarcinoma carcinoma | 1.57 ± 0.10 | 4.68 ± 0.29 | 0.86 ± 0.08 |
| MDA-MB-231 | Breast epithelial adenocarcinoma | 3.53 ± 0.19 | 7.16 ± 0.37 | 1.34 ± 0.21 |
| 2008 | Ovarian carcinoma | 1.91 ± 0.23 | 21.81 ± 2.92 | 2.24 ± 0.16 |
| HCT116 | Colorectal carcinoma | 1.09 ± 0.41 | 5.62 ± 0.33 | 1.40 ± 0.07 |
| UPCI:SCC104 | Oral squamous carcinoma | 6.87 ± 0.54 | 2.98 ± 0.22 | 1.13 ± 0.18 |
| PCI 15A | Head and neck squamous carcinoma | 0.26 ± 0.03 | 0.41 ± 0.04 | 1.86 ± 0.14 |
| PCI 15B | Head and neck squamous carcinoma | 0.34 ± 0.03 | 0.94 ± 0.20 | 1.81 ± 0.27 |
| PCI 37A | Head and neck squamous carcinoma | 0.53 ± 0.07 | 0.66 ± 0.06 | 2.51 ± 0.06 |
| PCI 37B | Head and neck squamous carcinoma | 0.26 ± 0.02 | 0.49 ± 0.05 | 3.58 ± 0.45 |
| UMSCC22A | Head and neck squamous carcinoma | 0.40 ± 0.06 | 1.45 ± 0.24 | 3.27 ± 0.70 |
| WI-38 Confluent | Fibroblasts | >100 | ND | >100 |
| WI-38 Proliferating | Fibroblasts | 1.74 ± 0.78 | 8.58 ± 0.78 | 1.54 ± 0.13 |
a
IC50 values are mean of 8 determinations.